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Abstract
Microsatellite instability (MSI) is caused by defective DNA mismatch repair (MMR),
and manifests as accumulation of small insertions and deletions (indels) in short tan-
dem repeats of the genome. Another form of repeat instability, elevated microsatel-
lite alterations at selected tetranucleotide repeats (EMAST), has been suggested to
occur in 50% to 60% of colorectal cancer (CRC), of which approximately one quarter
are accounted for by MSI. Unlike for MSI, the criteria for defining EMAST is not con-
sensual. EMAST CRCs have been suggested to form a distinct subset of CRCs that
has been linked to a higher tumor stage, chronic inflammation, and poor prognosis.
EMAST CRCs not exhibiting MSI have been proposed to show instability of di- and
trinucleotide repeats in addition to tetranucleotide repeats, but lack instability of
mononucleotide repeats. However, previous studies on EMAST have been based on
targeted analysis of small sets of marker repeats, often in relatively few samples. To
gain insight into tetranucleotide instability on a genome-wide level, we utilized whole
genome sequencing data from 227 microsatellite stable (MSS) CRCs, 18 MSI CRCs,
3 POLE-mutated CRCs, and their corresponding normal samples. As expected, we
observed tetranucleotide instability in all MSI CRCs, accompanied by instability of
mono-, di-, and trinucleotide repeats. Among MSS CRCs, some tumors displayed
more microsatellite mutations than others as a continuum, and no distinct subset of
tumors with the previously proposed molecular characters of EMAST could be
observed. Our results suggest that tetranucleotide repeat mutations in non-MSI
CRCs represent stochastic mutation events rather than define a distinct CRC
subclass.
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1 | INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer in Western
countries with a mortality rate of nearly 50%.1 In 1992 to 1993, insta-
bility of short repeated nucleotide sequences, microsatellites, was dis-
covered in sporadic and hereditary CRC, and was subsequently
named microsatellite instability (MSI).2 MSI was observed in approxi-
mately 15% of CRCs; in virtually all CRCs from Lynch syndrome
patients (3% of all CRCs) and in a subset of sporadic cases (12% of all
CRCs). Shortly thereafter, MSI was linked to a defect in the DNA mis-
match repair (MMR) machinery, one of the central mechanisms
involved in the recognition and repair of DNA replication errors. MSI
was found to arise from biallelic inactivation of an MMR gene.2,3 An
individual with Lynch syndrome inherits a heterozygous germline
mutation in an MMR gene (MLH1, MSH2, MSH6, or PMS2) and is
therefore highly predisposed to MSI CRC.2 Sporadic MSI CRCs most
often result from biallelic hypermethylation of MLH1. Inactivation of
the MMR system results in the accumulation of a high number of
mutations across the genome, mostly small insertions and deletions
(indels) in microsatellites of different orders, including tetranucleotide
repeats.4 Subsequently, MSI has also been observed in other cancer
types, for example in 10% to 20% of endometrial and gastric cancers.5
In 1997, The National Cancer Institute agreed on a panel of five
microsatellites, the Bethesda panel, that consists of two mononucleo-
tide and three dinucleotide microsatellites, as the reference for deter-
mining MSI in CRC.6 Tumors with instability in two or more markers
were considered to show a high level of MSI (MSI-H). Tumors with
instability in only one marker were considered to show a low level of
MSI (MSI-L). Since then, however, MSI-L CRCs have been shown to
exhibit clinical and molecular features identical to microsatellite stable
(MSS) CRCs.2,7-12
Subsequently, another form of repeat instability, elevated micro-
satellite alterations at selected tetranucleotide repeats, or EMAST, has
been suggested to occur in approximately 50% to 60% of all
CRCs.13-16 Unlike for MSI, no consensus criteria for determining
EMAST have been established, and different panels of markers with
different thresholds for calling EMAST have been used.15,17 EMAST
has been proposed to result from a dysfunction of MSH3 (MutS
homolog 3), one of the proteins involved in human MMR.14,15,18,19
However, the connection between MSH3 and EMAST does not
appear as straightforward as the well-established relationship
between the loss of expression of MLH1, MSH2, MSH6 or PMS2, and
MSI.15
To our knowledge, EMAST has not been reported to depend on a
total loss of MSH3 expression, and loss of expression of MSH3 has
been reported not to correlate with the number of unstable
tetranucleotide repeats observed, although this observation was
based on only five tetranucleotide repeats.20 Instead, heterogeneous
loss of expression of MSH3—resulting from its reversible shift from
the nucleus to the cytoplasm in response to interleukin-6 (IL6) and
hypoxia—together with its decreased expression, has been proposed
to be the mechanism behind EMAST.15,20,21 However, heterogeneous
expression of MSH3 has also been observed in CRCs not showing
EMAST.20 To our understanding, a causal relation between somatic
MSH3 mutations or epimutations and EMAST has not been proven.15
Compound heterozygous germline mutations in MSH3 have been
reported in two unrelated patients with adenomatous polyposis,
resulting in a complete loss of MSH3 as observed by immunohisto-
chemical staining.22 EMAST was suggested to be present in adenomas
of these patients.
Tetranucleotide instability appears to occur in all MSI CRCs,
where a defect in MLH1, MSH2, MSH6, or PMS2 leads to an accumula-
tion of indels in repeats.14,20,23 Yet, MSI CRCs and EMAST CRCs have
been suggested to constitute two separate entities, and among CRCs
that do not exhibit MSI, EMAST tumors have been proposed to form
a subset of CRCs that show instability of tetra-, di-, and trinucleotide
repeats, but not mononucleotide repeats.15,17,24 In contrast to MSI,
EMAST has been suggested to modify tumor behavior rather than
participate in the initiation of tumorigenesis.15,25 In CRC, EMAST has
been reported to be linked to a higher tumor stage, chronic inflamma-
tion, and poor prognosis.15,20,26 In addition to CRC, EMAST has been
suggested to occur in other cancer types, including lung, ovarian, pros-
tate, renal, endometrial, nonmelanoma skin cancer, and cancers of the
head and neck with prevalences varying from 9% to 75%.17 EMAST
has been suggested to relate to exposure to environmental carcino-
gens.17 It has also been proposed to show potential for serving as a
prognostic or preventive biomarker.16,17,27
In the past, MSI and EMAST studies were largely based on PCR
and subsequent fragment analysis of selected repeat sites, as there
was no technology to enable genome-wide depiction of repeat insta-
bility. In the past decade, however, next generation sequencing (NGS)
technologies have been widely accepted in both research and clinical
use. These technologies finally enable the genome-wide characteriza-
tion of mutations in tumors, including many of the repetitive regions.
To date, several large-scale sequencing efforts in CRC have been pub-
lished.8-10,12,28-41 These studies have confirmed MSI CRCs as a clearly
distinct subset of CRCs, especially in terms of the number of indels in
short repeated regions.8-10,12,28,29,31,33,34,41 However, none of these
large-scale studies have had a particular focus on tetranucleotide
repeats. In order to comprehensively characterize tetranucleotide
repeat instability on a genome-wide level, we utilized whole genome
sequencing (WGS) data from 227 MSS CRCs, 18 MSI CRCs, 3 POLE-
mutated CRCs, and their respective normal samples. To our knowl-
edge, this is the first effort focusing on EMAST at the genomic level.
We identified 561 490 tetranucleotide repeats in the human refer-
ence genome, and indels of a multiple of four in length were found in
30 306 of them in our WGS data. In our data, however, striking
tetranucleotide instability was only observed in MSI CRCs, coincident
with instability in mono-, di-, and trinucleotide repeats. Among MSS
CRCs, no distinct subgroup of tumors with characteristics fitting
EMAST was found. In order to confirm these observations, we per-
formed PCR and subsequent fragment analysis of five tetranucleotide
markers in 18 MSI, 3 POLE-defective, and 40 MSS CRCs. Also in the
fragment analysis data, MSI CRCs formed a clear subset of samples
with the most tetranucleotide instability. Some MSS samples showed
occasional tetranucleotide mutations, and these tumors tended to be
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the ones displaying many short repeat mutations in WGS data in
general.
2 | MATERIALS AND METHODS
2.1 | Ethics approval
This study was approved by the Ethics Committee of the Hospital Dis-
trict of Helsinki and Uusimaa, and conducted in accordance with the
Declaration of Helsinki. For all samples, signed informed consent was
given by the patient, or authorization was received from the National
Supervisory Authority for Welfare and Health.
2.2 | Patient material
In this study, fresh frozen specimens of colorectal adenocarcinomas,
and corresponding normal colorectal tissue samples or blood from
248 CRC patients in Finland were analyzed. These samples were
derived from a population-based series of CRCs from 1042 patients,
and a second series of CRCs from two regional hospitals for which
collection is ongoing.42
The MSI status of the tumors had been previously determined by
radioactive labeling techniques, fluorescence-based PCR methods or frag-
ment analysis in previous studies.42-44 In the radioactive labeling tech-
niques, seven markers (D5S404, D17S787, D5S346, D1S216, D11S904,
D10S197, and TP53) were analyzed by two reviewers. A sample was
called MSI if 2/7 markers were unstable. If none of the markers were
unstable, the sample was called MSS given that at least 5/7 markers were
successfully analyzed. If 1/7 markers were unstable, more markers (DCC,
D13S175, D7S519, D20S100, D15S120, D2S136, and D14S79) were
analyzed so that at least 10 markers were reviewed in total. If one or
more of the extra markers were unstable, the sample was called MSI. If
none of the markers were unstable, the sample was called MSS.
In cases where a fluorescence-based PCR method was utilized,
16 markers (D8S254, MYC, NM23, D5S346, TP53, D1S228, D8S261,
D7S496, D8S137, DCC, D7S501, MCC, D5S318, D1S507, D19S394,
and RB1) were tested for. If at minimum 30% of the alleles were unsta-
ble, the sample was called MSI. Later, two markers (BAT26 and TGFBRII)
were utilized. Both markers were evaluated by two independent
reviewers. If BAT26 showed deletions, the result was compared to that
of the normal sample to ensure the change was of somatic origin.
When fragment analysis was utilized, the Bethesda panel of five
markers (BAT25, BAT26, D5S346, D17S250, and D2S123) was analysed.6
If at least 2/5 markers showed instability, the sample was called MSI.
Of the 248 tumors, 18 fulfilled the criteria for MSI-H, and
230 were MSS, of which 2 were from patients with ulcerative colitis,
and three displayed an ultramutator phenotype caused by somatic
POLE defects (Supplementary Table 1).29 All MSI samples were spo-
radic; no germline mutation in an MMR gene had been detected in
these patients, the patients typically had no family history of CRC,
and did not develop CRC at a young age (Supplementary Table 1).
These tumors are known to nearly always relate to biallelic somatic
hypermethylation of the MLH1 promoter.45 Detailed clinical informa-
tion and a pathologist's evaluation were available for all samples.
2.3 | Whole genome sequencing
DNA was extracted from either fresh frozen tissue or blood using
standard methods. Whole-genome sequencing was carried out for the
CRC samples, and their corresponding normal pairs.46 Paired-end
sequencing was performed with Illumina HiSeq 2000 as an Illumina
service, or Illumina HighSeq X Ten as a SciLifeLab service. Read
lengths were 100 and 151 bp, and the median coverage was 47.6 and
28.3, respectively.
2.4 | Somatic variant calling and quality control
Primary analysis and somatic variant calling were performed with
GATK4 best practices workflow (version 4.0.4.0.) for all tumor/normal
pairs. The GRCh38 reference genome was used in all analyses. All var-
iants that were given a “PASS” filter value by Mutect2 were included.
In order to include all somatic variants at repeat sites, variants anno-
tated with “str_contraction” and “panel_of_normals” filter values were
also included.
2.5 | Variants in different repeat regions
We included all tetranucleotide repeats in the genome with at least
three consecutive repeat units. For the tetranucleotide repeat analy-
sis, all other repeat orders within tetranucleotide repeats were
excluded (eg, mono- and dinucleotide repeats). We considered all
somatic indel calls that were located precisely at the start of the
repeat region and that were multiples of four-base pairs in length (ie,
the length of a tetranucleotide repeat unit). For a subsequent analysis,
mono-, di-, and trinucleotide repeats were studied similarly, with the
exception of mononucleotide repeats where at least five consecutive
repeat units were required. BasePlayer was used for the annotation
and visual validation of repeats and variants.47
2.6 | Data plotting
Data was plotted with R using the ggplot2 library.48,49 The maximum
likelihood negative binomial fit was performed with the function glm.
nb from the MASS package (Mean = 63.38, dispersion = 4.79).50
2.7 | Fragment analysis of tetranucleotide markers
Fragment analysis was performed for 60 tumor-normal pairs; 17 MSI,
3 POLE-defective, and a subset of 40 MSS samples. Fragment analysis
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was also performed for one unpaired MSI tumor where normal tissue
was no longer available. The MSS tumors were uniformly selected
based on the number of unstable tetranucleotide repeats identified
from the WGS data: samples were ranked from highest to lowest by
the number of indels in their tetranucleotide repeats and approxi-
mately every sixth sample was selected for fragment analysis, based
on availability of sample material. Five tetranucleotide markers—
MYCL1, D20S85, D20S82, D8S321, and D9S242—were amplified by
PCR (Table 1).51 Each PCR reaction contained 0.15 μL AmpliTaqGold
(Applied Biosystems, Waltham, MA), 1.5 μL buffer (Applied Bio-
systems), 0.2 μL dNTPs (BioNordika, Helsinki, Finland), 0.6 μL
fluorescent-tagged forward primer (ThermoFisher Scientific, Life
Technologies, Waltham, MA), 0.6 μL reverse primer (Sigma-Aldrich,
St. Louis, MO), 9.95 μL water, and approximately 10 ng DNA
extracted from a fresh-frozen tumor. The PCR conditions consisted of
an initial denaturation at 95C for 10 minutes, followed by 35 cycles
of denaturation at 95C for 30 seconds, annealing at 60C for
75 seconds, and extension at 72C for 1 minute, before a final exten-
sion step at 72C for 30 minutes.
Fragment analysis was performed by capillary electrophoresis at
the Institute for Molecular Medicine Finland Technology Centre
(FIMM; Helsinki, Finland) with the ABI3730XL DNA Analyzer with
GeneScan 500 LIZ size standard (Applied Biosystems). The manufac-
turer's instructions were followed for all methods.
GeneMarker software (SoftGenetics, State College, PA; Version
1.40) was used for analyzing the sequencing graphs. Tumor samples
were compared to their corresponding normal sample. A marker was
considered unstable if a fragment length difference between the
tumor and normal sample of a multiple of 4 bp was seen. Fragment
analysis peaks in the tumor DNA were called if they had a height of at
least 20% that of the adjacent wildtype allele peak for 4 bp deletions,
and at least 10% for 4 bp insertions (Supplementary Figure 1). These
cut offs were not used for indels of 8 bp or longer as we did not
observe stutter peaks of these lengths in the normal DNA. A sample
was considered to show tetranucleotide instability when two or more
markers were unstable.
3 | RESULTS
In order to comprehensively characterize tetranucleotide repeat insta-
bility on a genome-wide level, we utilized WGS data from 227 MSS
CRCs, 18 MSI CRCs, 3 POLE-mutated CRCs, and their respective nor-
mal samples. Indels in tetranucleotide repeats were evaluated to
determine whether any tumor subgroups with EMAST could be
found. In total, 561 490 tetranucleotide repeats were identified in the
reference genome. Across all 248 CRCs, a total of 49 040 indels of a
multiple of four bases in length were observed in 30 306 different
tetranucleotide repeats.
3.1 | MSI CRCs harbored the most indels in
tetranucleotide repeats
The number of somatic indels in tetranucleotide repeats was com-
pared across all CRCs. MSI CRCs were clearly distinct from MSS
CRCs, with MSI tumors consistently containing a higher number of
indels (Figure 1A). The median number of indels in tetranucleotide
repeats in MSI tumors was 1866, while only 58 in MSS tumors. The
number of tetranucleotide indels in MSI CRCs was more variable with
over dispersion approximately 5-fold that of the MSS CRCs (95% CI
bootstrap estimates [7.7-13.5] and [25.5-123] for MSS and MSI,
respectively).
3.2 | No subset of MSS CRCs with tetranucleotide
instability was observed
Among MSS CRCs, distinct groups of tumors with differing numbers
of indels in tetranucleotide repeats were not found. Instead, the num-
ber of indels observed in tetranucleotide repeats was consistent with
random sampling from a negative binomial distribution (Kolmogorov-
Smirnov test, P-value > .05; Figure 1B). Similarly, when considering
the proportion of indels found in tetranucleotide repeats compared to
all indels in MSS CRCs, there was continuous variation across tumors
and a small number of samples with a very slightly higher or lower
proportion than expected by binomial distribution (Supplementary
Figure 2).
3.3 | POLE-mutated CRCs harbored a large number
of indels in tetranucleotide repeats
Three MSS tumors were POLE-mutated and had a tetranucleotide
repeat indel count in between that of the MSI and the remaining MSS
tumors (Figure 1A). They show greater similarity to other MSS tumors
in this regard. The proportion of indels in tetranucleotide repeats in
these samples, however, was particularly low in comparison to other
TABLE 1 Primer sequences of the
EMAST microsatellite markers
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MSS CRCs, and was instead indistinguishable from the MSI CRCs
(Supplementary Figure 3). Because both germline and somatic POLE-
mutations have been shown to coexist with somatic MMR gene muta-
tions and result in MSI CRC, we looked at somatic mutations in MMR
genes in these three samples (Supplementary Table 2).9,52-54 Each
sample contained subclonal somatic mutations in several MMR genes,
and at least one nonsense mutation in an MMR gene was found in
each sample. These subclonal changes provide a conceivable explana-
tion for the observed rate of repeat instability.
3.4 | Only a small proportion of indels were
located in tetranucleotide repeats, and deletions were
more prominent than insertions
In order to take into account the distribution of indels throughout
the genome, the proportion of somatic indels located within
tetranucleotide repeats was calculated for each tumor. With the
exception of the POLE-mutated MSS samples, the tumors still showed
clear separation based on their MMR status (Supplementary Figure 3).
Although the number of indels in tetranucleotide repeats was higher
in MSI tumors, they made up a smaller proportion of the indels
throughout the genome. A median of 0.36% and 1.14%, and a maxi-
mum of 0.45% and 2.65% of indels were located in tetranucleotide
repeats in MSI CRCs and MSS CRCs respectively. Therefore, in all
tumors, only a small minority of indels were located in tetranucleotide
repeats.
The majority of tumors harbored more deletions than insertions
within tetranucleotide repeats (Figures 1C,D). The difference was par-
ticularly prominent in MSI CRCs in which a median of only 25.2% of
indels were insertions (17.2%-40.1%). In MSS CRCs, the difference
was more subtle with a median of 47.2% of indels being insertions
(11.1%-75%). Approximately a third of MSS CRCs (87/230) contained
a higher number of insertions than deletions (Figures 1C,D).
3.5 | Longer tetranucleotide repeats and simple
tetra motifs were the most prone to indels
A large number of indels are located in the shortest tetranucleotide
repeats (Supplementary Figure 4). However, when the number of
tetranucleotide repeats of each length in the reference genome is
F IGURE 1 Somatic indels in tetranucleotide repeats. A, The number of all somatic indels in tetranucleotide repeats in all 248 CRCs. B, Q-Q
plot showing the observed number of somatic indels in tetranucleotide repeats in 227 MSS CRCs and three POLE-mutated CRCs. The solid black
line represents the expected distribution. C, The number of somatic deletions compared to the number of somatic insertions in tetranucleotide
repeats in all 248 CRCs. The Y-axis is on a log scale. D, A log-log plot showing the number of somatic insertions and somatic deletions in all
248 CRCs. The dashed line represents a 1:1 ratio of insertions and deletions. CRC, colorectal cancer; MSS, microsatellite stable
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taken into account, only a small proportion of the short tetranucleotide
repeats are targeted by indels (Figure 2A). Instead, when the number of
tetranucleotide repeats of each length in the reference genome is
accounted for, tetranucleotide repeats consisting of 11 tetra units are
most frequently targeted by indels. As the number of repeated units
increases beyond 11, a sharp drop in indel counts is observed. This dis-
tribution is seen in both MSS and MSI CRCs (Figure 2A). In longer
repeats, indels are likely to be underrepresented due to limitations in
current sequencing technologies.
A high proportion of tetranucleotides of 29 repeats appear to
contain indels (Figure 2A); however, this is due to the small number of
repeats in the genome of this length. Only two were identified in the
reference genome, one of which contained an indel in a single tumor.
Tetranucleotide repeats of particular motifs contained a higher num-
ber of indels than others (Supplementary Table 3). Repeats of simple
motifs such as AAAT, TTTA, AAAG, and TTTC contained the highest
number of indels.
3.6 | Short indels were more common in
tetranucleotide repeats
In this study, only indels that are a multiple of four nucleotides in length
were considered in the analysis. Figure 2B depicts indels of all lengths that
were observed in tetranucleotide repeats in the 248 CRCs. This figure
illustrates that the vast majority of indels in tetranucleotides are indeed a
multiple of four nucleotides in length, with their frequency decreasing as
the indel length becomes longer. Insertions in particular are preferentially
shorter in length (Supplementary Figure 5). Four-base deletions were the
most common indels observed.
F IGURE 2 Somatic indels in mono-, di-, tri-, and tetranucleotide repeats. A, The number of somatic indels in tetranucleotide repeats of
different lengths in all 248 CRCs as a proportion of the number of tetranucleotide repeats in the GRCh38 reference genome. MSI samples—the
number of indels in tetranucleotide repeats in the 18 MSI CRCs/18/the number of such tetranucleotide repeats in the reference genome. MSS
samples—the number of indels in tetranucleotide repeats in the 227 MSS CRCs and three POLE-mutated CRCs/230/the number of such
tetranucleotide repeats in the reference genome. B, The lengths of the somatic indels observed in tetranucleotide repeats in all the 248 CRCs up
to 40 bp. Unlike elsewhere in this study, in this figure, indels of all lengths are considered instead of only indels that are a multiple of four bases in
length. C, The number of somatic indels located within mono-, di-, tri-, and tetranucleotide repeats in all 248 CRCs as a proportion of the total
number of corresponding repeats in the GRCh38 reference genome. Mononucleotide repeats of at least 5 units in length were included, and di-,
tri-, and tetranucleotide repeats of at least 3 units in length. The Y-axis is on a log scale. D, The number of tetranucleotide repeat indels identified
in WGS data in relation to the number of unstable tetranucleotide markers observed in fragment analysis for 17 MSI, 3 POLE-defective, and
40 MSS tumors. The Y-axis is on a log scale. CRC, colorectal cancer; MSI, microsatellite instability; MSS, microsatellite stable
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3.7 | Indels in tetranucleotide repeats in four
protein coding genes were observed
The majority of tetranucleotide repeats are in noncoding regions of
the genome. However, 207 of the tetranucleotide repeats that were
identified overlap with the coding sequence of protein coding genes
(Supplementary Table 4). A deletion was observed in four genes:
BRCA2, DLG3, MEPE, and ZNF66 (Table 2). Each gene contained a
deletion in only one tumor.
3.8 | Instability of mono-, di-, and trinucleotide
repeats was observed in MSI CRCs but not in
MSS CRCs
Because EMAST CRCs have been suggested to show instability in di-
and trinucleotide repeats in addition to tetranucleotide repeats, but
absence of instability in mononucleotide repeats, we looked at the
number of indels observed in mono-, di-, and trinucleotide repeats in
our 248 CRCs (Supplementary Table 5).15,24 All MSI CRCs showed a
high indel count in mono-, di-, and trinucleotide repeats in addition to
tetranucleotide repeats (Figure 2C). In MSI CRCs, a particularly high
proportion of indels were observed in mononucleotides, a median of
91.4%, as opposed to 4.6%, and 0.2% in di-, and trinucleotides,
respectively. In MSS CRCs, no subsets of tumors were observed to
have a higher indel count for any of these repeat lengths (Figure 2C).
In MSS CRCs, a lower proportion of indels were observed in mononu-
cleotide repeats than in MSI CRCs (median 69.5%), whereas a higher
proportion of indels was observed in di- and trinucleotide repeats
(median 7.6% and 0.7%, respectively; Supplementary Figures 6-8).
When the number of indels in mono-, di, tri-, and tetranucleotide
repeats was compared to the number of such repeats in the genome,
mononucleotide repeats are the most mutated, followed by
tetranucleotide, dinucleotide, and trinucleotide repeats (Figure 2C,
Supplementary Table 6).
A simple linear regression was applied to the MSS samples and
the number of tetranucleotide repeat indels was found to be strongly
correlated with both the number of mononucleotide (adjusted R2
0.6213, P < 2e−16) and dinucleotide repeat indels (adjusted R2 0.5251,
P < 2e−16; Supplementary Figure 9).
3.9 | MSS tumors with a high number of indels
tend to display a proximal location, higher age, and
higher sequencing coverage
Clinical characteristics were compared between the MSS tumors in
the top and bottom thirds by the number of mono-, di-, tri-, and
tetranucleotide repeat indels (Supplementary Table 7). No significant
difference was observed at a significance level below 0.05 in regards
to sex, Duke's stage, tumor grade, or the immune cell score (T cell
infiltration) with any repeat unit length. The tumor location (Fisher's
exact test, all P < .027), age of the patient at diagnosis and the average
read coverage on variant in WGS data (Wilcoxon rank sum test, all
P < .022 and P < .021, respectively) were identified as being signifi-
cantly different with all repeat unit lengths. MSS tumors in the upper
third of the spectrum more often tended toward a proximal location
(Supplementary Figure 10), higher age (for tetra indels, median 71 and
69, and range 50-91 and 28-87, for top and bottom thirds, respec-
tively), and a higher average coverage (for tetra indels, mean 45.7 and
42.5, and SD 9.21 and 9.57, for top and bottom thirds, respectively)
than tumors with a high number of indels.
3.10 | The number of unstable tetranucleotide
markers in fragment analysis does not fully reflect
genome-wide tetranucleotide instability in WGS data
Fragment analysis was performed for all 18 MSI and 3 POLE-defec-
tive, and 40 of the MSS tumors selected to represent samples across
the whole range of tetranucleotide repeat indel counts (Figure 2D).
Five tetranucleotide markers (MYCL1, D20S85, D20S82, D8S321, and
D9S242) traditionally used to call EMAST were utilized.51 The unsta-
ble markers for each tumor are shown in Supplementary Table 8.










MEPE s26.1 T1 MSI 4:87845066 G- > del4 Het(20/69) 0.29 Matrix extracellular phosphoglycoprotein
(Source: HGNC Symbol%3BAcc:
HGNC:13361)
BRCA2 c206.1 T1 MSS 13:32332778 A- > del4 Het(11/50) 0.22 BRCA2%2C DNA repair associated
(Source: HGNC Symbol%3BAcc:
HGNC:1101)
ZNF66 c39.1 T MSI 19:20799053 T- > del4 Het(4/20) 0.20 Zinc finger protein 66 (Source: HGNC
Symbol%3BAcc:HGNC:13135)
DLG3 c777.1 T MSI X:70492526 A- > del4 Het(4/37) 0.11 Disks large MAGUK scaffold protein 3
(Source: HGNC Symbol%3BAcc:
HGNC:2902)
Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable.
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Consistent with the WGS data, all 18 MSI tumors showed
tetranucleotide instability in fragment analysis, defined here as insta-
bility in two or more of the five markers (Figure 2D). For one of the
MSI tumors, matching normal DNA was not available for fragment
analysis, but the tumor harbored three alleles for two of the markers
in the tumor DNA and so was inferred as unstable. The majority of
MSI tumors showed instability in four or five markers and only two in
fewer than four markers (Figure 2D). The majority of MSS samples
and all three POLE-defective samples showed instability in zero or one
markers (57.5% and 22.5%, respectively, for MSS samples). Thus, con-
sistent with the WGS data, these samples did not show
tetranucleotide instability according to fragment analysis. However,
seven of the MSS tumors showed instability in two, and one MSS
tumor in four markers, and thus, in contrast to WGS, appeared to
show tetranucleotide instability in fragment analysis (Figure 2D).
Overall, in the fragment analysis, 20% of MSS tumors showed
tetranucleotide instability while in the WGS data no tetranucleotide
instability was observed in these tumors.
The MSS tumors with two or four unstable markers in fragment
analysis were typically in the upper end of the spectrum of WGS
tetranucleotide repeat indel counts, while tumors with only one
unstable marker were typically in the lower end (Supplementary Fig-
ure 11). Notably, MSS tumors with no unstable markers were inter-
spersed among the MSS tumors with unstable markers throughout
the whole spectrum of WGS tetranucleotide repeat indel counts
(Supplementary Figure 11).
In MSS samples, each additional unstable marker associates with
approximately 20% more (10%-34%, Bayesian Negative Binomial
model, 95% High-Density Interval) tetranucleotide repeat indels in
WGS on average and the distributions of indel counts with a given
number of unstable markers are highly overlapping (Figure 2D). None
of the five markers are significantly correlated with any (Fisher's exact
test) or all (logistic regression) others in our dataset of MSS samples.
4 | DISCUSSION
Previously, the study of repetitive regions of the genome mostly con-
sisted of targeted fragment analysis of selected repeat sites as no
technology enabling genome-wide characterization of repeat muta-
tions was available. MSI was discovered in the early 1990s through
shortening or lengthening of short tandem repeats in approximately
15% of CRCs, and was soon linked to defective DNA MMR2. Subse-
quently, another form of repeat instability, EMAST, has been
suggested to occur in approximately 50% to 60% of which approxi-
mately one quarter are accounted for by MSI CRCs.13-16,20,23 The
emergence of NGS and the ensuing large-scale sequencing studies
have confirmed mutation accumulation in the genome to be non-
uniform, and the mutability of repeated regions is affected by factors
such as their length, nucleotide composition and genomic loca-
tion.9,10,12,30,31,55 Therefore, genome-wide studies are required to
obtain a comprehensive picture of repeat instability in cancer. Large-
scale sequencing studies on CRC have confirmed MSI CRCs to be a
distinct subset of CRC with a large number of mutations, especially
indels in their short tandem repeats.8-10,12,28,29,31,33,34,41 To our
knowledge, however, EMAST has not been studied on the genome-
wide level before. Hence, in order to gain a comprehensive picture of
tetranucleotide repeat instability in CRC, we utilized WGS data from
227 MSS CRCs, 18 MSI CRCs, 3 POLE-mutated CRCs, and their
respective normal samples.
We identified 561 490 tetranucleotide repeats in the human ref-
erence genome and from these found 30 306 indels of a multiple of
four bases in length in our WGS data. In accordance with previous
large-scale sequencing efforts in CRC, MSI was evident in our WGS
data as the MSI tumors harbored the most indels in repeat regions
(Supplementary Table 3).8-10,12,28,29,31,33,34,41,43,44 Instability of
tetranucleotide repeats was observed in all 18 MSI CRCs as antici-
pated (Figure 1A).14,20,23 Indels in CRCs exhibiting MSI have been
reported to occur most prominently in mononucleotide repeats, but
also in other short repeats. This was observed in our data as the MSI
tumors exhibited indels in mono-, di-, and trinucleotide repeats in
addition to tetranucleotide repeats (Figure 2C).9,15,24,31 When the
number of indels observed was compared to the number of such
repeats in the reference genome, mononucleotide repeats were the
most highly mutated, followed by tetranucleotide, dinucleotide, and
trinucleotide repeats (Figure 2C). This is most likely explained by a rel-
atively high number of longer, more unstable, tetranucleotide repeats
in the human genome.
It has been suggested that a group of CRCs that does not exhibit
MSI shows EMAST.13-16 However, in our WGS data, no subset of
MSS CRCs with specific tetranucleotide instability was identified
(Figures 1A,B). Overall, in MSS CRCs, tetranucleotide repeats were
fairly stable with a median of 58 indels in tetranucleotide repeats per
tumor, compared to a median of 1866 in MSI CRCs. Of note, the
sequencing technology used is not suitable for observing very long
tetranucleotide repeats, such as those that have traditionally been
used for determining EMAST (MYCL1, D20S85, D8S321, D20S82,
and D9S242), because their length hampers alignment of the
sequence reads.26,31 In order to confirm this observation, we per-
formed PCR and subsequent fragment analysis of these five
tetranucleotide markers in 18 MSI, 3 POLE-defective, and 40 MSS
CRCs. Also in this data, only the MSI CRCs formed a clear subset of
samples showing the highest numbers of unstable markers (typically
four or five) and consistent tetranucleotide instability (Figure 2D).
Among MSS CRCs, no distinct subset of tumors with EMAST could be
detected, the majority showing no unstable markers while several
tumors showed one or two (Figure 2D). In MSS samples, each addi-
tional unstable marker associates with proportional increase in the
number of tetranucleotide repeat indels in WGS, and instabilities in
the five markers appear uncorrelated. Taken together, all this indicates
the marker instability in MSS tumors as a proxy for the continuum of
tetranucleotide repeat indel counts, instead of being discriminant of a
separate group of tumors. Furthermore, this is consistent with the
Negative Binomial distribution of the indel counts in population
(Figure 1B) being formed by Gamma-Poisson mixture, where each
repeat mutation appears independently from others, given a tumor
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specific, Gamma distributed, base mutation rate. The variation of this
base mutation rate can be largely attributed to features such as age of
the patient, tumor location, and sequencing depth. A higher number
of tetranucleotide repeat indels in MSS tumors WGS data was also a
predictor for a higher number of mono- and dinucleotide repeat indels
in the same tumor. Therefore, based on our results, the presence of
one or two unstable tetranucleotide markers in fragment analysis—
both criteria traditionally used to detect EMAST—simply predicts a
somewhat higher number of short repeat mutations in general.15,17
EMAST CRCs have been suggested to show instability in di-, and
trinucleotide repeats in addition to instability in tetranucleotide
repeats, but absence of mononucleotide repeat instability.15,24 In our
WGS data, however, striking tetranucleotide instability was always
observed together with instability in mono-, di-, and trinucleotide
repeats, and solely in MSI CRCs (Figure 2C). Our observation that
tetranucleotide instability is observed in MSI CRCs is compatible with
two other large-scale CRC sequencing studies where indels in
tetranucleotide repeats were observed.9,31 Instability of dinucleotide
repeats with no instability in mononucleotide repeats has been
claimed to be a hallmark of the so-called MSI-L phenotype, and MSI-L
and EMAST have been suggested to be either the same or an over-
lapping phenomenon.14,15,23,56 In our WGS data, however, no such
subset of tumors with sole dinucleotide instability was observed
(Figure 2C). This, too, is in line with previous large-scale CRC sequenc-
ing efforts.9,10 The number of tetranucleotide repeat indels in MSS
tumors was found to be strongly correlated with the numbers of
mono- and dinucleotide repeat indels, reinforcing the proposed over-
lap of the phenomena reported previously as EMAST and MSI-L. The
findings from our data support the view that repeat mutations in
tumors without MSI represent stochastic mutation events with the
presence of intact MMR systems, and MSI-L and EMAST as such are
not biologically relevant subtypes of CRC.
The clinical correlates between tumors of high and low-repeat
indel count were highly similar when analyzing repeats of any unit
length, with tetranucleotide repeats in no way distinguishing from
mono-, di-, or trinucleotide repeats. The slight excess number of
repeat indels in MSS tumors on the upper end of the spectrum may
partially be due to the observed higher age of these patients at diag-
nosis, allowing increased time for mutations to accumulate, as well as
the higher average sequencing coverage. Tumors with a high number
of repeat indels of any unit length were located proximally slightly
more often than tumors with a low-repeat indel count. Although we
detected no difference in tumor stage between these groups, this ten-
dency could be related to tumor age, proximal tumors perhaps requir-
ing a longer time from initiation to removal.
In the WGS data, among the MSS CRCs, the three POLE-mutated
CRCs were amidst those with the highest number of indels in
tetranucleotide repeats, and the same was observed for mono-, di-,
and trinucleotide repeats (Figures 1A and 2C). Strikingly elevated sin-
gle nucleotide variation (SNV) rates in particular have been previously
reported in POLE-mutated tumors.8 However, in a study by Kim et al,
one POLE-mutated CRC genome and one POLE-mutated endometrial
genome were reported to harbor MLH1 silencing and result in an MSI
phenotype.9 Subsequently, both germline and somatic POLE-
mutations have been shown to coexist with somatic MMR gene muta-
tions and result in MSI CRC.52-54 Indeed, in our data, we observed
somatic subclonal mutations in MMR genes in the POLE-mutated sam-
ples (Supplementary Table 2). The resulting MMR deficient subclones
provide a plausible explanation as to why POLE tumors, despite in
general being MSS, display relatively many repeat mutations in the
genome-wide NGS data.
According to Watson et al, in most EMAST cancers, instability
occurs at loci with AAAG or ATAG motifs.17 Also in our WGS data,
these were among the most highly mutated motifs (Supplementary
Table 3). Of the indels observed in tetranucleotide repeats, deletions
were more common than insertions, especially in MSI CRCs
(Figures 1C,D). In tumors with MSI as well as in the POLE-mutated
tumors, a smaller proportion of all indels was observed in
tetranucleotide repeats than in MSS samples (Figure 2A and Supple-
mentary Figure 3). For the MSI CRCs, this was not surprising given
that mononucleotide repeats have been shown to accumulate the
most indels in these tumors.9,31
We identified 207 tetranucleotide repeats in protein coding
genes in the human reference genome (Supplementary Table 4). Of
these, indels were observed in only four genes (BRCA2, MMPE, DLG3,
and ZNF66), of which all contained a deletion in one tumor (Table 2).
BRCA2 (BRCA2 DNA repair associated) is a previously well-established
cancer gene involved in homologous recombination, and its germline
mutations cause hereditary breast and ovarian cancer.57 MMPE
(matrix metalloproteinase E) encodes a secreted calcium-binding
phosphoprotein that has been identified as a co-factor of the check-
point kinase CHK1 and protects cells from DNA damage induced kill-
ing.58 It has also been suggested to serve as a target for sensitizing
human tumor cells to radiotherapy or chemotherapy.59 DLG3, also
known as MPP3 (membrane palmitoylated protein 3), encodes a mem-
ber of the membrane-associated guanylate kinase protein family. Epi-
genetic inactivation of MPP3 has been shown to occur frequently
during CRC development through promoter hypermethylation.60
ZNF66 (zinc finger protein 66) has to our knowledge not been linked
to cancer. Whether any of these mutations have contributed to gene-
sis of the respective tumors is unclear, as cancer genomes may con-
tain hundreds to thousands of mutations, and most of the mutations
are merely background mutations that do not drive tumorigenesis.61
In recent years, MSI has been the target of growing interest due
to the associated generation of immunogenic tumor antigens and con-
siderable potential for targeted immunotherapies.62 In addition to
MSI, EMAST has been suggested to cause repeat instability in
CRC.13-16 However, the definition of EMAST has varied between dif-
ferent studies, and to date the studies have relied on the sequencing
of a small set of tetranucleotide repeats and mostly in small sample
sets.14,18-20,22,23,63 EMAST CRCs have been suggested to portray a
distinct clinicopathological profile, and some studies have found asso-
ciations between EMAST and a higher histological state, chronic
inflammation, and poor prognosis.15,20,26 Hence, EMAST has been
suggested to be a biomarker in CRC.16,17,27 In our study, which to our
knowledge is the first genome-wide study focusing on tetranucleotide
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instability, we found no evidence for EMAST as a separate entity.
Instead, instability of tetranucleotide repeats was observed in tumors
exhibiting MSI, and stochastically in MSS CRCs with higher numbers
of any microsatellite mutations. Thus, similar to MSI-L, no evidence
was found to support EMAST as a character defining a particular sub-
class of CRC.
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